Business Development Strategy

Eyetech Pharmaceuticals is an innovative ophthalmic biopharmaceutical company focusing on diseases of the eye. Our capabilities span the spectrum of biopharmaceutical development including discovery, clinical development, and commercialization of novel therapies to treat ophthalmic diseases. We are comprised of distinguished experts in ophthalmology and vision research. We have recognized expertise in clinical development, and an experienced commercial team. With Macugen® (pegaptanib sodium injection), we have demonstrated our capabilities in moving a compound rapidly and efficiently through the development process and believe that this is a core strength of Eyetech, making it a preferred partner.

Eyetech is pursuing in-licensing and product development partnerships to further expand our product line in ophthalmology. Eyetech's strategic direction for partnering is directed by the following:

Clinical stage candidates: Eyetech seeks products that are being investigated in the clinic, or can quickly enter clinical development.

Therapeutics for the back of the eye: Products for back of the eye diseases will complement our commercial capabilities for Macugen® (pegaptanib sodium injection).

Ophthalmic drug delivery systems: We seek novel methods to deliver pharmaceuticals to the back of the eye.

Non-ophthalmic indications for Macugen® (pegaptanib sodium injection): We are interested in partnering for the development of Macugen® (pegaptanib sodium injection) for use outside of ophthalmology.

Other Ophthalmic Indications: Eyetech is interested in pursuing novel approaches toward treating other diseases in the eye, such as glaucoma and inflammation, as part of our future company growth.

Eyetech as a Partner

Eyetech is a biopharmaceutical company driven by the desire to develop and commercialize novel therapies for unmet medical needs in ophthalmology. We have proven expertise in ophthalmic research and development. Our ophthalmic focus allows us to move potential therapeutics rapidly from the lab bench through clinical trials. For instance, we licensed Macugen® (pegaptanib sodium injection), our lead compound for treating the wet form of age-related macular degeneration, from Gilead Sciences in April of 2000 while it was still in phase 1 clinical trials. We plan to file an NDA in the 3rd quarter of 2004, clearly demonstrating our ability to move a program toward commercialization.

In addition to our known ophthalmic expertise, partners of Eyetech will have access to a team of scientists, clinicians, and professionals with experience at leading biotechnology and pharmaceutical companies. Accomplishments of the Eyetech team include:

• 90 filed NDAs
• 107 product launches
• 51 FDA Advisory Committee meetings
• 60 alliance teams
• >300 peer-reviewed articles